Framingham, MA, United States of America

Lakshmi Bhagat

This inventor holds 33 USPTO granted patents and 19 published patent applications, plus 3 CIPO patents and 6 EPO patents, primarily in Immunomodulatory Oligonucleotides. Top assignee: Idera Pharmaceuticals, Inc.. Active years: 2007-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lakshmi Bhagat. Retrieved from https://idiyas.com/inventor/lakshmi-bhagat

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 (Patent Applications = 19)

% Patents Active = 33.3

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 6 (Patent Applications = 19)

Average Co-Inventor Count = 5.0

ph-index = 13

Forward Citations = 648(Granted Patents)

Location History:

Brookline, MA (US) (2007 - 2013)
Cambridge, MA (US) (2015)
Framingham, MA (US) (2009 - 2016)

Company Filing History:

33 out of 80

Idera Pharmaceuticals, Inc.

patents

Years Active: 2007-2016

Loading Chart...

Areas of Expertise:

Immune Regulatory Oligonucleotides

Toll-Like Receptor Modulators

Stabilized Immunomodulatory Oligonucleotides

Synthetic Agonists of TLR9

Immunostimulatory Properties

Gene Expression Inhibition

Immunomers

Cancer Treatment

Short Immunomodulatory Oligonucleotides

RNA Compounds

5' End Presentation

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9453228 - Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response (2016-09-27),

2. 9206430 - Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response (2015-12-08),

3. 8946175 - Stabilized immunomodulatory oligonucleotides (2015-02-03),

4. 8853375 - Toll like receptor modulators (2014-10-07),

5. 8431544 - Compositions for inhibiting gene expression and uses thereof (2013-04-30),

6. 8426375 - Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response (2013-04-23),

7. 8399423 - Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response (2013-03-19),

8. 8383598 - Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response (2013-02-26),

9. 8377898 - Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response (2013-02-19),

10. 8362233 - Stabilized immune modulatory RNA (SIMRA) compounds (2013-01-29),

11. 8361986 - Synthetic agonists of TLR9 (2013-01-29),

12. 8357665 - Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response (2013-01-22),

13. 8202850 - Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends (2012-06-19),

14. 8188261 - Stabilized immune modulatory RNA (SIMRA) compounds (2012-05-29),

15. 8153777 - Modulation of toll-like receptor 5 expression by antisense oligonucleotides (2012-04-10),

Title: Innovations by Lakshmi Bhagat in Immune Regulatory Oligonucleotides

Introduction

Lakshmi Bhagat is a distinguished inventor based in Framingham, MA, with an impressive portfolio of 33 patents to his name. His innovative work primarily focuses on immune regulatory oligonucleotides, contributing significantly to the advancement of immune response modulation.

Latest Patents

Among his latest inventions, Bhagat has developed immune regulatory oligonucleotide (IRO) compounds that serve as antagonists of toll-like receptors (TLRs). These unique oligonucleotides have a profound ability to inhibit or suppress TLR-mediated signaling triggered by TLR ligands or agonists. The applications of these compounds span across various medical fields, offering potential solutions for the prevention and treatment of cancer, autoimmune disorders, airway inflammation, inflammatory disorders, infectious diseases, skin disorders, allergies, asthma, and diseases caused by pathogens.

Career Highlights

Lakshmi Bhagat’s career is marked by his significant contributions in the pharmaceutical sector, particularly with Idera Pharmaceuticals, Inc. His innovative research and inventions continue to shape the landscape of immunotherapy and related fields.

Collaborations

Throughout his career, Bhagat has collaborated with notable professionals in the industry, including Sudhir Agrawal and Ekambar R Kandimalla. These collaborations have enriched his research and contributed to the successful development of his patented innovations.

Conclusion

Lakshmi Bhagat's work exemplifies the critical intersection of innovation and healthcare. His patents in immune regulatory oligonucleotides position him as a key figure in the ongoing efforts to enhance therapeutic strategies against various diseases. With continued research and development, Bhagat is poised to make a lasting impact on medical treatments and patient outcomes.

Profile summary based on public USPTO records.